MedCity News September 13, 2024
Frank Vinluan

Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs.

Cancers of the head and neck can be treated with several drugs on the market, but for certain patients diagnosed with this this common type of cancer, outcomes are worse and better therapeutic options are needed. Bicara Therapeutics is developing a therapy that could provide a treatment alternative and the company now has $315 million in IPO cash to finance a pivotal study.

Boston-based Bicara was able to raise more than it planned. In preliminary IPO terms set...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Investments, Pharma / Biotech, Trends
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
City Therapeutics' $135m debut, and other bio financing news
Leverage AI to Lower Cost, Barriers to Cell Therapies
Robust Evidence Synthesis To Support Transparent Medicare Drug Price Negotiation
New Analysis Compares Sustainable Diet Habit Results to Those of GLP-1s

Share This Article